Sodium alginate is the sodium salt of alginic acid. Sodium alginate can be extracted and isolated from brown algae kelp. Sodium alginate may be utilized in food additives and pharmaceuticals, adsorbs heavy metal ions and has mucosal protection and hemostatic effects.

Physicochemical Properties

Molecular Formula	C6H7O6NA
Molecular Weight	216.12303
Exact Mass	216.024
CAS #	9005-38-3
PubChem CID	23665711
Appearance	White to light brown solid
Melting Point	119 °C
Source	Seaweed Laminaria japonica
Hydrogen Bond Donor Count	4
Hydrogen Bond Acceptor Count	7
Rotatable Bond Count	1
Heavy Atom Count	14
Complexity	210
Defined Atom Stereocenter Count	5
SMILES	[Na+].O1[C@H]([C@H]([C@H]([C@@H](C1C(=O)[O-])O)O)O)O
InChi Key	MSXHSNHNTORCAW-WTFUTCKNSA-M
InChi Code	InChI=1S/C6H10O7.Na/c7-1-2(8)4(5(10)11)13-6(12)3(1)9;/h1-4,6-9,12H,(H,10,11);/q;+1/p-1/t1-,2-,3-,4-,6+;/m0./s1
Chemical Name	sodium;(2S,3S,4S,5S,6R)-3,4,5,6-tetrahydroxyoxane-2-carboxylate
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture.
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

Targets	Natural product
ln Vitro	With the development of modern industry, heavy metal pollution is one of the most important environmental issues. Due to its simplicity and low-cost, adsorption is considered as a green and environmental friendly method to remove heavy metals from industrial effluents. Sodium alginate is a natural polysaccharide, which consists of abundant hydroxyl and carboxyl groups, has been widely reported as the raw material for the adsorption of heavy metals from aqueous solutions. By surface grafting and cross-linking, adsorbents synthesized from sodium alginate have exhibited large uptake capacities as well as high removal rates for heavy metal ions. However, the poor physical strength and plain thermostability have significantly limited the utilization of sodium alginate based materials in industrial applications. Moreover, reductions of specific metal ions were observed in some studies, of which the reduction mechanism is not clearly clarified. In this work, the development of sodium alginate based adsorbents was summarized, including the physicochemical properties of the polymer, the modification of sodium alginate, sodium alginate based composite materials, and the adsorption behaviors as well as the mechanism. Chelation, electrostatic interaction, ion exchange, reduction and photocatalytic reduction were involved in the adsorption process, which can be determined by chemical characterization with further elucidation by density functional theory calculation. Finally, the limitations of sodium alginate based adsorbents were revealed with suggestions for future research[2].
ln Vivo	Rats that receive a single intradermal and subcutaneous injection of sodium alginate (0.1–0.5 mL; parietal periosteum) have granulomatous reactions[1].
Animal Protocol	Animal/Disease Models: 8weeks old male Wistar rats[1] Doses: 0.1-0.5 mL Route of Administration: Parietal periosteum , intradermal and subcutaneous (sc) injection; 0.2, 0.1 and 0.5 mL respectively, once Experimental Results: Induced macrophages recruitment and generated skin uplift. Filler injection demand is increasing worldwide, but no ideal filler with safety and longevity currently exists. Sodium alginate (SA) is the sodium salt of alginic acid, which is a polymeric polysaccharide obtained by linear polymerization of two types of uronic acid, d-mannuronic acid (M) and l-guluronic acid (G). This study aimed to evaluate the therapeutic value of SA. Nine SA types with different M/G ratios and viscosities were tested and compared with a commercially available sodium hyaluronate (SH) filler. Three injection modes (onto the periosteum, intradermally, or subcutaneously) were used in six rats for each substance, and the animals were sacrificed at 4 or 24 weeks. Changes in the diameter and volume were measured macroscopically and by computed tomography, and histopathological evaluations were performed. SA with a low M/G ratio generally maintained skin uplift. The bulge gradually decreased over time but slightly increased at 4 weeks in some samples. No capsule formation was observed around SA. However, granulomatous reactions, including macrophage recruitment, were observed 4 weeks after SA implantation, although fewer macrophages and granulomatous reactions were observed at 24 weeks. The long-term volumizing effects and degree of granulomatous reactions differed depending on the M/G ratio and viscosity. By contrast, SH showed capsule formation but with minimal granulomatous reactions. The beneficial and adverse effects of SA as a filler differed according to the viscosity or M/G ratio, suggesting a better long-term volumizing effect than SH with relatively low immunogenicity.
ADME/Pharmacokinetics	Absorption, Distribution and Excretion Apparently ... not decomposed or absorbed appreciably when ingested ... When propyleneglycol (14)C alginate or (14)C propylene glycol alginate ... dosed to mice, unhydrolyzed ester and alginate residue ... unabsorbed from GI tract; but any hydrolyzed propyleneglycol ... absorbed ... metabolized and eliminated ... single dose ... 1 g/kg ... excreted ... feces ... 5 days ... ... After a dose of 5 g/kg, traces of label were still present in rectum. Alginate prepared from laminaria digitata was unabsorbed by rats fed at a level of 10% of their daily diet.
References	[1]. Sodium Alginate as a Potential Therapeutic Filler: An In Vivo Study in Rats. Mar Drugs. 2020 Oct 19;18(10):520. [2]. Adsorption of heavy metal ions by sodium alginate based adsorbent-a review and new perspectives. Int J Biol Macromol. 2020 Dec 1;164:4423-4434.

Solubility Data

Solubility (In Vitro)

H2O: 6.67 mg/mL

Solubility (In Vivo)

Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	4.6271 mL	23.1353 mL	46.2706 mL
	5 mM	0.9254 mL	4.6271 mL	9.2541 mL
	10 mM	0.4627 mL	2.3135 mL	4.6271 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.